{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:52:19Z","timestamp":1756191139097,"version":"3.30.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,30]]},"DOI":"10.7759\/cureus.74840","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T16:29:38Z","timestamp":1732984178000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Management of Severe and Refractory Autoimmune Hemolytic Anemia (AIHA) in a Sickle Cell Disease Patient With Bortezomib"],"prefix":"10.7759","author":[{"given":"Mohammed A","family":"Alanssari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaf","family":"Al-Sulaitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Al-Sulaitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaad A","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qutaiba M","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo B","year":"2022","unstructured":"Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol. 2022, 18:731-45. 10.1080\/1744666X.2022.2089115","journal-title":"Expert Rev Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.08.001","article-title":"New therapies for the treatment of warm autoimmune hemolytic anemia","volume":"36","author":"Fattizzo B","year":"2022","unstructured":"Fattizzo B, Barcellini W. New therapies for the treatment of warm autoimmune hemolytic anemia. Transfus Med Rev. 2022, 36:175-80. 10.1016\/j.tmrv.2022.08.001","journal-title":"Transfus Med Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051035","article-title":"Development of new drugs for autoimmune hemolytic anemia","volume":"14","author":"Xiao Z","year":"2022","unstructured":"Xiao Z, Murakhovskaya I. Development of new drugs for autoimmune hemolytic anemia. Pharmaceutics. 2022, 14:1035. 10.3390\/pharmaceutics14051035","journal-title":"Pharmaceutics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000405","article-title":"Warm autoimmune hemolytic anemia and the best treatment strategies","volume":"2022","author":"Kuter DJ","year":"2022","unstructured":"Kuter DJ. Warm autoimmune hemolytic anemia and the best treatment strategies. Hematology Am Soc Hematol Educ Program. 2022, 2022:105-13. 10.1182\/hematology.2022000405","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200405000-00011","article-title":"Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease","volume":"26","author":"Raj A","year":"2004","unstructured":"Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol. 2004, 26:312-4. 10.1097\/00043426-200405000-00011","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale R","year":"2021","unstructured":"Pasquale R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol. 2021, 12:20406207211046428. 10.1177\/20406207211046428","journal-title":"Ther Adv Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v16i4.10877","article-title":"Prevalence of splenomegaly and splenic complications in adults with sickle cell disease and its relation to fetal hemoglobin","volume":"16","author":"Lakhani JD","year":"2022","unstructured":"Lakhani JD, Gill R, Mehta D, Lakhani SJ. Prevalence of splenomegaly and splenic complications in adults with sickle cell disease and its relation to fetal hemoglobin. Int J Hematol Oncol Stem Cell Res. 2022, 16:198-208. 10.18502\/ijhoscr.v16i4.10877","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger U","year":"2020","unstructured":"J\u00e4ger U, Barcellini W, Broome CM, et al.. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020, 41:100648. 10.1016\/j.blre.2019.100648","journal-title":"Blood Rev"},{"key":"ref9","article-title":"Combined sickle cell disease and autoimmune hemolytic anemia","volume":"141","author":"Chaplin H Jr","year":"1981","unstructured":"Chaplin H Jr, Zarkowsky HS. Combined sickle cell disease and autoimmune hemolytic anemia. Arch Intern Med. 1981, 141:1091-3.","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam S","year":"2016","unstructured":"Ratnasingam S, Walker PA, Tran H, et al.. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016, 1:31-5. 10.1182\/bloodadvances.2016001412","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker LD","year":"2020","unstructured":"Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020, 60:457-76. 10.1146\/annurev-pharmtox-010919-023603","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert K","year":"2008","unstructured":"Neubert K, Meister S, Moser K, et al.. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008, 14:748-55. 10.1038\/nm1763","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu393","article-title":"Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient","volume":"54","author":"Wang Y","year":"2015","unstructured":"Wang Y, Zhou W, Zhang Z. Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology (Oxford). 2015, 54:194-5. 10.1093\/rheumatology\/keu393","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03976-w","article-title":"Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia","volume":"99","author":"Chen M","year":"2020","unstructured":"Chen M, Zhuang J, Yang C, et al.. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol. 2020, 99:1141-3. 10.1007\/s00277-020-03976-w","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah J","year":"2019","unstructured":"Fadlallah J, Michel M, Crickx E, et al.. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol. 2019, 187:124-8. 10.1111\/bjh.16009","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04135-x","article-title":"Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia","volume":"100","author":"Ames PR","year":"2021","unstructured":"Ames PR, Jeffrey S. Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia. Ann Hematol. 2021, 100:2415-6. 10.1007\/s00277-020-04135-x","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.12.010","article-title":"Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with bortezomib in combination with plasma exchange","volume":"199","author":"Tkachenko O","year":"2019","unstructured":"Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Mikhailova L, Gilburd B. Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with bortezomib in combination with plasma exchange. Clin Immunol. 2019, 199:44-6. 10.1016\/j.clim.2018.12.010","journal-title":"Clin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill QA","year":"2017","unstructured":"Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017, 176:395-411. 10.1111\/bjh.14478","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini W","year":"2018","unstructured":"Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018, 14:857-72. 10.1080\/1744666X.2018.1521722","journal-title":"Expert Rev Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini W","year":"2020","unstructured":"Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1. J Clin Med. 2020, 9:3859. 10.3390\/jcm9123859","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284748-successful-management-of-severe-and-refractory-autoimmune-hemolytic-anemia-aiha-in-a-sickle-cell-disease-patient-with-bortezomib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T16:29:39Z","timestamp":1732984179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284748-successful-management-of-severe-and-refractory-autoimmune-hemolytic-anemia-aiha-in-a-sickle-cell-disease-patient-with-bortezomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.74840","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}